Mapping the dose-effect relationship of orbofiban from sparse data with an artificial neural network

Journal of Pharmaceutical Sciences

Volumn 94, Issue 11, 2005, Pages 2475-2486

  Mager, Donald E ^a,d   Shirey, Jason D ^a,e   Cox, Dermot ^b   Fitzgerald, Desmond J ^c   Abernethy, Darrell R ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^c UNIVERSITY COLLEGE DUBLIN   (Ireland)

^d UNIVERSITY AT BUFFALO   (United States)

^e Washington DC   (United States)

Author keywords

Dose response; Humans; Mathematical model; Neural networks; Orbofiban; Pharmacodynamics; Population pharmacodynamics

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; FIBRINOGEN RECEPTOR ANTAGONIST; LOTRAFIBAN; ORBOFIBAN;

ACCURACY; ADULT; AGED; ARTICLE; ARTIFICIAL NEURAL NETWORK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DOSE RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL; THROMBOCYTE AGGREGATION INHIBITION; VALIDATION PROCESS;

EID: 30544446631     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.20384     Document Type: Article

References (21)

1. Nies AS. 2001. Principles of therapeutics. In: Hardman JG, Limbird LE, Gilman AG, editors. The pharmacological basis of therapeutics, 10th ed., New York: The McGraw-Hill Companies, Inc. pp 45-66.
2. Levy G. 1998. Predicting effective drug concentrations for individual patients. Determinants of pharmacodynamic variability. Clin Pharmacokinet 34:323-333.
3. Baxt WG. 1995. Application of artificial neural networks to clinical medicine. Lancet 346:1135-1138.
4. Brier ME, Aronoff GR. 1996. Application of artificial neural networks to clinical pharmacology. Int J Clin Pharmacol Ther 34:510-514.
5. Gobburu JV, Chen EP. 1996. Artificial neural networks as a novel approach to integrated pharmacokinetic-pharmacodynamic analysis. J Pharm Sci 85:505-510.
6. Chow HH, Tolle KM, Roe DJ, Elsberry V, Chen H. 1997. Application of neural networks to population pharmacokinetic data analysis. J Pharm Sci 86:840-845.
7. Haidar SH, Johnson SB, Fossler MJ, Hussain AS. 2002. Modeling the pharmacokinetics and pharmacodynamics of a unique oral hypoglycemic agent using neural networks. Pharm Res 19:87-91.
8. Gaweda AE, Jacobs AA, Brier ME, Zurada JM. 2003. Pharmacodynamic population analysis in chronic renal failure using artificial neural networks-a comparative study. Neural Netw 16:841-845.
9. Martin Guerrero JD, Olivas ES, Valls GC, Serrano Lopez AJ, Perez Ruixo JJ, Torres NV. 2003. Use of neural networks for dosage individualisation of erythropoietin in patients with secondary anemia to chronic renal failure. Comput Biol Med 33:361-373.
10. Urquidi-Macdonald M, Mager DE, Mascelli MA, Frederick B, Freedman J, Fitzgerald DJ, Kleiman NS, Abernethy DR. 2004. Abciximab pharmacodynamic model with neural networks used to integrate sources of patient variability. Clin Pharmacol Ther 75:60-69.
11. Veng-Pedersen P, Modi NB. 1993. Application of neural networks to pharmacodynamics. J Pharm Sci 82:918-926.
12. Anders R, Kleiman J, Nicholson N, Wazowicz B, Burns D. 2001. Xemilofiban/orbofiban: Insight into drug development. Cardiovasc Drug Rev 19:116-132.
13. Nicholson NS, Abood NA, Panzer-Knodle SG, Frederick LG, Page JD, Salyers AK, Suleymanov OD, Szalony JA, Taite BB, Anders RJ. 2001. Orbofiban: An orally active GPIIb/IIIa platelet receptor antagonist. Med Res Rev 21:211-226.
14. Newby LK, Califf RM, White HD, Harrington RA, Van de Werf F, Granger CB, Simes RJ, Hasselblad V, Armstrong PW. 2002. The failure of orally administered glycoprotein IIb/IIIa inhibitors to prevent recurrent cardiac events. Am J Med 112:647-658.
15. Cox D, Smith R, Quinn M, Theroux P, Crean P, Fitzgerald DJ. 2000. Evidence of platelet activation during treatment with a GPIIb/IIIa antagonist in patients presenting with acute coronary syndromes. J Am Coll Cardiol 36:1514-1519.
16. Erb R. 1993. Introduction to backpropagation neural network computation. Pharm Res 10:165-170.
17. Sheiner LB, Beal SL. 1981. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 9:503-512.
18. Steinhubl SR, Kottke-Marchant K, Moliterno DJ, Rosenthal ML, Godfrey NK, Coller BS, Topol EJ, Lincoff AM. 1999. Attainment and maintenance of platelet inhibition through standard dosing of abciximab in diabetic and nondiabetic patients undergoing percutaneous coronary intervention. Circulation 100:1977-1982.
19. Abernethy DR, Pezzullo J, Mascelli MA, Frederick B, Kleiman NS, Freedman J. 2002. Pharmacodynamics of abciximab during angioplasty: Comparison to healthy subjects. Clin Pharmacol Ther 71:186-195.
20. Mager DE, Mascelli MA, Kleiman NS, Fitzgerald DJ, Abernethy DR. 2003. Simultaneous modeling of abciximab plasma concentrations and ex vivo pharmacodynamics in patients undergoing coronary angioplasty. J Pharmacol Exp Ther 307:969-976.
21. Mould D, Chapelsky M, Aluri J, Swagzdis J, Samuels R, Granett J. 2001. A population pharmacokinetic-pharmacodynamic and logistic regression analysis of lotrafiban in patients. Clin Pharmacol Ther 69:210-222.